Zulresso
Total Payments
$429,711
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $124,827 | 2 | 0 |
| 2023 | $304,884 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $429,711 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder | Sage Therapeutics, Inc. | $226,767 | 0 |
| Open Label Study of the Efficacy, Safety and Tolerability of Zulresso in the Treatment of Adult Womenwith Postpartum Psychosis | Sage Therapeutics, Inc. | $74,886 | 0 |
| Dynamic neural mechanisms of brexanolone-induced antidepressant effects in postpartum depression: Afeasibility study | Sage Therapeutics, Inc. | $49,941 | 0 |
| Dynamic neural mechanisms of brexanolone-induced antidepressant effects in postpartum depression | Sage Therapeutics, Inc. | $39,953 | 0 |
| An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Brexanolone in the Treatment of Adult Participants with Tinnitus | Sage Therapeutics, Inc. | $38,164 | 0 |
Top Doctors Receiving Payments for Zulresso
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Austin, TX | $429,711 | 6 |
Ad
Manufacturing Companies
- Sage Therapeutics, Inc. $429,711
Product Information
- Type Drug
- Total Payments $429,711
- Total Doctors 0
- Transactions 6
About Zulresso
Zulresso is a drug associated with $429,711 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Sage Therapeutics, Inc..
Payment data is available from 2023 to 2024. In 2024, $124,827 was paid across 2 transactions to 0 doctors.
The most common payment nature for Zulresso is "Unspecified" ($429,711, 100.0% of total).
Zulresso is associated with 5 research studies, including "An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder" ($226,767).